Literature DB >> 21968514

Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy.

Karen K Y Ling1, Rebecca M Gibbs, Zhihua Feng, Chien-Ping Ko.   

Abstract

Spinal muscular atrophy (SMA), a motoneuron disease caused by a deficiency of the survival of motor neuron (SMN) protein, is characterized by motoneuron loss and muscle weakness. It remains unclear whether widespread loss of neuromuscular junctions (NMJs) is involved in SMA pathogenesis. We undertook a systematic examination of NMJ innervation patterns in >20 muscles in the SMNΔ7 SMA mouse model. We found that severe denervation (<50% fully innervated endplates) occurs selectively in many vulnerable axial muscles and several appendicular muscles at the disease end stage. Since these vulnerable muscles were located throughout the body and were comprised of varying muscle fiber types, it is unlikely that muscle location or fiber type determines susceptibility to denervation. Furthermore, we found a similar extent of neurofilament accumulation at NMJs in both vulnerable and resistant muscles before the onset of denervation, suggesting that neurofilament accumulation does not predict subsequent NMJ denervation. Since vulnerable muscles were initially innervated, but later denervated, loss of innervation in SMA may be attributed to defects in synapse maintenance. Finally, we found that denervation was amendable by trichostatin A (TSA) treatment, which increased innervation in clinically relevant muscles in TSA-treated SMNΔ7 mice. Our findings suggest that neuromuscular denervation in vulnerable muscles is a widespread pathology in SMA, and can serve as a preparation for elucidating the biological basis of synapse loss, and for evaluating therapeutic efficacy.

Entities:  

Mesh:

Year:  2011        PMID: 21968514      PMCID: PMC3235013          DOI: 10.1093/hmg/ddr453

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  53 in total

Review 1.  Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded.

Authors:  J P Julien
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

Review 2.  The neurobiology of childhood spinal muscular atrophy.

Authors:  T O Crawford; C A Pardo
Journal:  Neurobiol Dis       Date:  1996-04       Impact factor: 5.996

3.  Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.

Authors:  P E McAndrew; D W Parsons; L R Simard; C Rochette; P N Ray; J R Mendell; T W Prior; A H Burghes
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

4.  The effects of chronic episodic hypercapnic hypoxia on rat upper airway muscle contractile properties and fiber-type distribution.

Authors:  Michelle McGuire; Mary MacDermott; Aidan Bradford
Journal:  Chest       Date:  2002-10       Impact factor: 9.410

5.  Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases.

Authors:  D Frey; C Schneider; L Xu; J Borg; W Spooren; P Caroni
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

6.  SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN.

Authors:  Thanh T Le; Lan T Pham; Matthew E R Butchbach; Honglai L Zhang; Umrao R Monani; Daniel D Coovert; Tatiana O Gavrilina; Lei Xing; Gary J Bassell; Arthur H M Burghes
Journal:  Hum Mol Genet       Date:  2005-02-09       Impact factor: 6.150

7.  Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis.

Authors:  K Xu; S Jha; W Hoch; S E Dryer
Journal:  Neuroscience       Date:  2006-11-01       Impact factor: 3.590

Review 8.  Assembly, plasticity and selective vulnerability to disease of mouse neuromuscular junctions.

Authors:  Alexandre Ferrão Santos; Pico Caroni
Journal:  J Neurocytol       Date:  2003 Jun-Sep

9.  Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy.

Authors:  Amy M Avila; Barrington G Burnett; Addis A Taye; Francesca Gabanella; Melanie A Knight; Parvana Hartenstein; Ziga Cizman; Nicholas A Di Prospero; Livio Pellizzoni; Kenneth H Fischbeck; Charlotte J Sumner
Journal:  J Clin Invest       Date:  2007-02-22       Impact factor: 14.808

Review 10.  Spinal muscular atrophy disease: a literature review for therapeutic strategies.

Authors:  M Stavarachi; P Apostol; M Toma; D Cimponeriu; L Gavrila
Journal:  J Med Life       Date:  2010 Jan-Mar
View more
  104 in total

1.  Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy.

Authors:  Tara L Martinez; Lingling Kong; Xueyong Wang; Melissa A Osborne; Melissa E Crowder; James P Van Meerbeke; Xixi Xu; Crystal Davis; Joe Wooley; David J Goldhamer; Cathleen M Lutz; Mark M Rich; Charlotte J Sumner
Journal:  J Neurosci       Date:  2012-06-20       Impact factor: 6.167

2.  Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.

Authors:  Nimrod Miller; Zhihua Feng; Brittany M Edens; Ben Yang; Han Shi; Christie C Sze; Benjamin Taige Hong; Susan C Su; Jorge A Cantu; Jacek Topczewski; Thomas O Crawford; Chien-Ping Ko; Charlotte J Sumner; Long Ma; Yong-Chao Ma
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

3.  AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy.

Authors:  E Villalón; R A Kline; C E Smith; Z C Lorson; E Y Osman; S O'Day; L M Murray; C L Lorson
Journal:  Hum Mol Genet       Date:  2019-11-15       Impact factor: 6.150

4.  Dissection of the transversus abdominis muscle for whole-mount neuromuscular junction analysis.

Authors:  Lyndsay Murray; Thomas H Gillingwater; Rashmi Kothary
Journal:  J Vis Exp       Date:  2014-01-11       Impact factor: 1.355

Review 5.  Disease mechanisms and therapeutic approaches in spinal muscular atrophy.

Authors:  Sarah Tisdale; Livio Pellizzoni
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

6.  Astrocytes influence the severity of spinal muscular atrophy.

Authors:  Hansjörg Rindt; Zhihua Feng; Chiara Mazzasette; Jacqueline J Glascock; David Valdivia; Noah Pyles; Thomas O Crawford; Kathryn J Swoboda; Teresa N Patitucci; Allison D Ebert; Charlotte J Sumner; Chien-Ping Ko; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2015-04-24       Impact factor: 6.150

7.  Chronic Pharmacological Increase of Neuronal Activity Improves Sensory-Motor Dysfunction in Spinal Muscular Atrophy Mice.

Authors:  Christian M Simon; Beatriz Blanco-Redondo; Jannik M Buettner; John G Pagiazitis; Emily V Fletcher; Josiane K Sime Longang; George Z Mentis
Journal:  J Neurosci       Date:  2020-11-20       Impact factor: 6.167

8.  SMN is required for sensory-motor circuit function in Drosophila.

Authors:  Wendy L Imlach; Erin S Beck; Ben Jiwon Choi; Francesco Lotti; Livio Pellizzoni; Brian D McCabe
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

9.  Selective loss of alpha motor neurons with sparing of gamma motor neurons and spinal cord cholinergic neurons in a mouse model of spinal muscular atrophy.

Authors:  Rachael A Powis; Thomas H Gillingwater
Journal:  J Anat       Date:  2015-11-17       Impact factor: 2.610

10.  Neurotransmitter release in motor nerve terminals of a mouse model of mild spinal muscular atrophy.

Authors:  Rocío Ruiz; Lucía Tabares
Journal:  J Anat       Date:  2013-03-13       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.